ClinicalTrials.gg
Not yet recruitingNCT07212712Updated Feb 10, 2026

The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

An interventional study of GnRH antagonist and Estradiol (E2) in Cerebral Blood Flow, Cerebral Blood Flow Regulation and Sex Differences, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Weeks to 40 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Weeks to 40 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Motor Activity by University of British Columbia — 24 open to participants now, 26 under way, none of them phase 3. Motor Activity · University of British Columbia.

Planned enrollment
57th of 92
50 · median 61
Started
2026
with 6 others
No phase
88 of 96
22 open now
Primary completion
2026-12
later than 9 of 25 live
Registered
89th of 96
by date

Among the 96 studies in Motor Activity by University of British Columbia, this one is the 57th largest by planned enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2026, is one of 88 with no phase, reaches primary completion later than 9 of the 25 other live ones, and was the 89th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

24 of the 96 studies in Motor Activity by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Weeks to 40 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Motor Activity by University of British Columbia, or all of them as a file.
02

Study summary

Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.

Read the detailed description

Sex hormones have been demonstrated to influence cardiovascular function in humans and cerebrovascular function in preclinical models. Declines in gonadal function have been attributed to the development of chronic disease risk in humans, including stroke, cognitive decline and dementia but the pathophysiology of these disorders remains unclear, in part, because there remains a gap-in-knowledge of the regulatory actions of sex hormones on cerebrovascular function in males and females. Therefore, the major goal of this application is to determine the independent regulatory actions of testosterone and estradiol on cerebrovascular function in males and females, respectively. Determination of this fundamental physiology is needed to inform future studies evaluating the sex-specific pathology physiology of chronic diseases and/or the development of efficacious sex-specific interventions for improving chronic disease risk.

To the investigator's knowledge, there is minimal evidence in humans isolating the influence of these hormones on basic mechanisms of brain blood flow regulation in vivo. Cross-sectional studies demonstrate younger females show significantly higher resting cerebral blood flow (CBF) compared to young males however, this sex difference in CBF is lost after midlife. This loss of female 'protection' on CBF is often attributed to hormonal differences following menopause. Further evidence in animal models support a key role of estrogen in both resting CBF and reactivity. Crucially, these findings have not been replicated in humans, due to natural fluctuations in sex hormones. Research investigating natural hormonal fluctuations throughout the menstrual cycle and menopause provides conflicting findings, falling short on isolating the specific hormonal influences on cerebrovascular physiology likely due large interindividual variations in hormone levels and cycle lengths.

Similarly, the presence of normal physiological levels of testosterone has been shown to influence chronic disease risk including cardiovascular disease risk and peripheral vascular function. However, whether testosterone concentrations influence CBF in males remains incompletely understood with one study showing testosterone may enhance CBF in older hypogonadal men. Furthermore, testosterone can be converted to estradiol via a specific enzyme, aromatase; thus, it is unclear whether the findings of prior study were related to changes in testosterone or estradiol concentrations in hypogonadal males. A definitive role of these hormones in brain blood flow regulation remains to be elucidated.

Current published studies suffer from several key limitations. First, many studies are unable to isolate the impact of hormones and their causality on cerebrovascular function in humans. The inability to replicate findings from direct hormone manipulation in animals with observational data during natural hormone cycling in humans suggests measuring females during their menstrual cycles is not adequate for understanding the direct role of these hormones. There is a very large degree of variation both between and within individuals throughout their menstrual cycles, proving difficult to relate changes in function with hormone levels. In males, very limited research exists investigating how testosterone influences cerebrovascular function. Further, this research will have direct implications for peri- and postmenopausal women, who are regularly prescribed exogenous estradiol for symptom management. Understanding the role of hormones in healthy physiology will allow direct translation to a myriad of hormonal disorders, including endometriosis, polycystic ovary syndrome, uterine fibroids, and hypogonadism. Individuals with endometriosis are commonly prescribed oral GnRH antagonist, which can be combined with estradiol for prolonged use (> 6 months). Similarly, males with hypogonadism often supplement testosterone for prolonged periods with minimal negative effects.

This study will allow for isolation of estradiol in females and testosterone in males to investigate their role on cerebrovascular regulation. In contrast with previous observational studies throughout the menstrual cycle and menopause in females and aging in males, this study will provide a controlled environment to determine causal relationships between hormones and physiology without the presence of confounding variables. This study will address the gap in literature between interventional models in animals and observational studies in healthy humans. This study will provide fundamental understandings of healthy physiology that will shape future studies to investigate the role of estradiol and testosterone in clinical populations.

The primary objective of this study is to determine how estrogen and testosterone influence cerebral blood flow and metabolism.

Primary Hypotheses:

  • Cerebral blood flow and cerebral metabolic rate of oxygen consumption will be reduced in females with hormone blockade but augmented with estrogen add-back.
  • Cerebral blood flow and cerebral metabolic rate of oxygen consumption will be increased in males with hormone blockade but attenuated with testosterone add-back.

To meet cerebral metabolic demands, the brain is dependent upon constant oxygen and nutrient delivery. Cerebral oxygen delivery is directly proportional to CBF and the arterial oxygen content (CaO2); it is widely known that CaO2 is lower in females, owing to the impact of anemia, hormones, and other related factors (e.g., hemoglobin, menses). To compensate, in order to maintain a stable cerebral oxygen delivery, females increase their resting CBF. Indeed, both CaO2 and hemoglobin levels are related to CBF levels. Very limited research has investigated whether cerebral metabolism differs between young males and females, with one study reporting a similar cerebral metabolic rate of oxygen (CMRO2), and another reporting higher CMRO2 in females. As cerebral metabolism is determined by CBF and the degree of oxygen extracted by the brain (oxygen extraction fraction; OEF), we must measure CMRO2 to appropriately interpret differences in CBF throughout our intervention.

Measuring CMRO₂ with the direct, invasive Fick method is the gold standard approach. By directly quantifying CBF and the arterial-venous difference in oxygen content, the Fick approach provides an absolute and internally consistent measure of brain oxygen consumption, rather than an indirect surrogate (as used with MRI, for example). This directness minimizes reliance on modeling assumptions and calibration factors that can introduce systematic bias in non-invasive techniques. As a result, Fick-based CMRO₂ measurements offer high accuracy and reproducibility; this approach is often used for validating newer imaging methods and for studies in which precise quantification of cerebral metabolism is essential. In terms of CBF, the majority of studies that of explored sex differences have typically incorporated measures of intracranial velocity via transcranial Doppler (TCD) rather than assessment flow. In this study, we will employ contemporary measures of Duplex ultrasound which measures extracranial flow and further validates our inclusion of CMRO2 measures.

Despite its invasiveness, the Fick method offers unique benefits that justify its use in select experimental and clinical contexts. Because it yields absolute metabolic values, the direct Fick method facilitates meaningful comparisons across subjects, conditions, and studies for the critical benchmark and gold-standard for understanding cerebral energetics. Compared with MRI-based approaches, the Fick technique quantifies CMRO2 from measured cerebral blood flow and the arterial-venous oxygen content difference, yielding an absolute metabolic rate with minimal dependence on modeling assumptions. In contrast, MRI-derived CMRO2 estimates typically rely on indirect contrasts (e.g., BOLD, ASL) and biophysical models that require assumptions about vascular geometry, baseline physiology (eg., hemoglobin levels), and coupling between flow, volume, and metabolism, all of which can vary across subjects and conditions. As a result, the invasive Fick method offers superior accuracy and interpretability, particularly when precise quantification is required or when validating MRI-based metabolic measurements. While PET imaging would be considered the gold standard to measure regional blood flow and oxygen or glucose metabolism by tracking the uptake of injected radioactive tracers (usually H₂¹⁵O), it is also invasive, requiring injected radioactive tracers and does not provide information on global CMRO2 or lactate metabolism. For a more extensive review of the limitations of PET imaging for global cerebral metabolism, please see Duffy et al. Therefore, neither PET nor MRI imaging can be easily used when common stressors are implemented (e.g., exercise, changes in partial pressures of oxygen and carbon dioxide) to provide an index of brain resilience.

03

Conditions studied

  • Cerebral Blood Flow
  • Cerebral Blood Flow Regulation
  • Sex Differences
  • Exercise
  • Vascular

Browse trials for

04

Who can participate

Ages eligible
18 Weeks to 40 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

The investigators will recruit healthy young (18-40 years) males (n = 25) and females (n = 25). Females must be naturally cycling (i.e., no oral or hormonal ), not pregnant, and premenopausal. Participants must be normotensive (\<140/90 mmHg \& >90/60 mmHg) and have no medical history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, and renal disease assessed by a study questionnaire. A recent physical examination (within 1 year of participation) from a family physician or a completed physical examination by the study doctor is required prior to participation. All subjects will sign an form prior to participation.

Participants will be excluded if they meet any of the following criteria:

  • Hypertensive (≥140/90 mmHg) or hypotensive (≤90/60 mmHg)
  • ≥ 30 kg/m2
  • Fasting blood glucose ≥ 100 mg/dL
  • Abnormal results on standard blood hematology tests (e.g., complete blood count, comprehensive metabolic panel)
  • Males with hypogonadism (total testosterone ≤ 262 ng/dL, per Endocrine Society recommendations)
  • Any history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, or renal disease
  • Any liver dysfunction or disease
  • Taking any cardiovascular medications or medications that would interfere with study medications (e.g., strong organic anion transporting polypeptide 1B1 inhibitors)
  • or sensitivities to study medications
  • Current eating disorder (defined as >2 on the 'SCOFF' questionnaire 67)
  • Current smokers
  • Females with an irregular menstrual cycle or any medical conditions affecting the menstrual cycle (normal cycle defined as 21-35 days from menstrual cycle diary)
  • Females who are pregnant (assessed with pregnancy test at screening and prior to starting medications), breastfeeding, or planning to conceive within 3 months
  • Females using hormonal birth control (Copper intrauterine devices [IUDs] will be allowed as they do not change systemic hormone levels)
  • Females who are peri- or (as determined by STRAW criteria 68)
  • History of hormone-sensitive cancers (i.e., breast, ovarian, uterine or prostate)
  • Z-score \< -2 as assessed with DXA scan (to determine risk of decrease in bone mineral density)
  • Assessed using the Center for Epidemiologic Studies Depression (CES-D) scale, participants with a score > 16 at screening unless otherwise approved by the study MD
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Hormone Manipulation

    Participants will act as their own controls, completing the experiment 3 times. First, with no hormone manipulation; second, with blockade of hormone production; third, with hormone add-back.

    Drug: GnRH antagonist · Drug: Estradiol (E2) · Drug: Testosterone · Drug: Anastrozole (Arimidex)

Interventions

06

What researchers measure

Primary outcomes

  1. Cerebral blood flow responses to estrogen and testosterone

    To determine how cerebral blood flow regulation is altered by estrogen and testosterone concentrations. Measured through doppler ultrasonography, and reported in mL/min.

    Time frame: 7 days

  2. Cerebral metabolic changes with estrogen and testosterone

    Measured as cerebral metabolic rate of oxygen consumption. Determined using arterial and internal jugular vein blood sampling coupled with doppler ultrasound, to determine metabolism directly using the Fick method.

    Time frame: 4 days

Secondary outcomes

  1. Hormone influences on appetite sensations

    How estrogen and testosterone influence appetite sensations (visual analog scale)

    Time frame: 7 days

  2. How estrogen and testosterone influence energy intake

    dietary intake, measured with self-report questionnaire

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Publications

  • Muer JD, Didier KD, Wannebo BM, Sanchez S, Khademi Motlagh H, Haley TL, Carter KJ, Banks NF, Eldridge MW, Serlin RC, Wieben O, Schrage WG. Sex differences in gray matter, white matter, and regional brain perfusion in young, healthy adults. Am J Physiol Heart Circ Physiol. 2024 Oct 1;327(4):H847-H858. doi: 10.1152/ajpheart.00341.2024. Epub 2024 Aug 9. PubMed 39120466 ↗
  • Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008 Oct;7(10):915-26. doi: 10.1016/S1474-4422(08)70193-5. Epub 2008 Aug 21. PubMed 18722812 ↗
  • Moreau KL, Hildreth KL, Klawitter J, Blatchford P, Kohrt WM. Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress. Geroscience. 2020 Dec;42(6):1699-1714. doi: 10.1007/s11357-020-00236-7. Epub 2020 Aug 8. PubMed 32770384 ↗

Individual participant data

Plan to share: Undecided — We will share individual data from published results on request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 8 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 8, 2025
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07212712
Responsible party
Phil Ainslie (Professor, University of British Columbia) — Principal investigator
First posted
Oct 8, 2025
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Lauren Maier, MSc
Contact
laurenm7@student.ubc.ca
250 878 6171
Philip Ainslie, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone

Start the discussion